



Clinical trial results:

Conventional ovarian stimulation vs. stimulation with single injection of Corifollitropin alfa in oocyte donors. Randomized clinical trial. Tail Studio

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2019-001343-44 |
| Trial protocol | ES |
| Global end of trial date | 08 May 2021 |

Results information

| | |
|-----------------------------------|-----------------------------------|
| Result version number | v1 (current) |
| This version publication date | 27 August 2022 |
| First version publication date | 27 August 2022 |
| Summary attachment (see zip file) | 2019-001343-44 (Tail_results.pdf) |

Trial information

Trial identification

| | |
|-----------------------|-------------|
| Sponsor protocol code | IB-0319-002 |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03939403 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Instituto Bernabeu |
| Sponsor organisation address | Av. Albufereta 31, Alicante, Spain, 03016 |
| Public contact | Anna Pitas, Instituto Bernabeu, 34 965154000, apitas@institutobernabeu.com |
| Scientific contact | Anna Pitas, Instituto Bernabeu, 34 965154000, apitas@institutobernabeu.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 16 February 2022 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 22 March 2021 |
| Global end of trial reached? | Yes |
| Global end of trial date | 08 May 2021 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To study the efficiency of the use of a single injection of CFA for ovarian stimulation, initiating administration late and without further contribution of FSH activity after the 7th day of stimulation compared to conventional EOC using CFA (administration of the drug 5 days after cesar hormonal contraceptive and supplementation with FSH daily administration from the 8th day of stimulation).

Protection of trial subjects:

Measures as per usual clinical practice.

Background therapy: -

Evidence for comparator: -

| | |
|---|--------------|
| Actual start date of recruitment | 03 June 2019 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------|
| Country: Number of subjects enrolled | Spain: 180 |
| Worldwide total number of subjects | 180 |
| EEA total number of subjects | 180 |

Notes:

Subjects enrolled per age group

| | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 180 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Recruitment among the oocyte donors at our clinic.

Pre-assignment

Screening details:

Completion of the screening criteria, normal ultrasound scan and normal hormonal analysis results.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|---------------|
| Are arms mutually exclusive? | Yes |
| Arm title | control group |

Arm description:

The used treatment is identical in both arms. The difference between the groups is the moment of beginning of the stimulation as well as the later administration of more FSH activity:
The control group receives the treatment on the 5th day after the cessation of hormonal contraceptive use and also receives additional FSH.

| | |
|--|-------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | ELONVA |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

SINGLE SUBCUTANEOUS INJECTION, 250 mcg ofcorifolitropine alfa

| | |
|------------------|-------------|
| Arm title | study group |
|------------------|-------------|

Arm description:

The used treatment is identical in both arms. The difference between the groups is the moment of beginning of the stimulation as well as the later administration of more FSH activity:
The intervention group receives the treatment on the 7th day after the cessation of hormonal contraceptive use and does not receive additional FSH.

| | |
|--|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | ELONVA |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

SINGLE SUBCUTANEOUS INJECTION, 250 mcg ofcorifolitropine alfa

| Number of subjects in period 1 | control group | study group |
|---------------------------------------|---------------|-------------|
| Started | 90 | 90 |
| Completed | 81 | 68 |
| Not completed | 9 | 22 |
| Physician decision | 9 | 11 |
| Covid | - | 3 |
| Lost to follow-up | - | 8 |

Baseline characteristics

Reporting groups

| | |
|--|---------------|
| Reporting group title | control group |
| Reporting group description: The used treatment is identical in both arms. The difference between the groups is the moment of beginning of the stimulation as well as the later administration of more FSH activity: The control group receives the treatment on the 5th day after the cessation of hormonal contraceptive use and also receives additional FSH. | |
| Reporting group title | study group |
| Reporting group description: The used treatment is identical in both arms. The difference between the groups is the moment of beginning of the stimulation as well as the later administration of more FSH activity: The intervention group receives the treatment on the 7th day after the cessation of hormonal contraceptive use and does not receive additional FSH. | |

| Reporting group values | control group | study group | Total |
|---|---------------|-------------|-------|
| Number of subjects | 90 | 90 | 180 |
| Age categorical Units: Subjects | | | |
| In utero | | | 0 |
| Preterm newborn infants (gestational age < 37 wks) | | | 0 |
| Newborns (0-27 days) | | | 0 |
| Infants and toddlers (28 days-23 months) | | | 0 |
| Children (2-11 years) | | | 0 |
| Adolescents (12-17 years) | | | 0 |
| Adults (18-64 years) | | | 0 |
| From 65-84 years | | | 0 |
| 85 years and over | | | 0 |
| Age continuous Units: years | | | |
| arithmetic mean | 24.52 | 24.52 | |
| standard deviation | ± 6.26 | ± 5.69 | - |
| Gender categorical Units: Subjects | | | |
| Female | 90 | 90 | 180 |
| Male | 0 | 0 | 0 |

Subject analysis sets

| | |
|---|--------------|
| Subject analysis set title | Tail |
| Subject analysis set type | Per protocol |
| Subject analysis set description: All oocyte donors included in the study were healthy women 18 - 32 years, with body mass index between 18 and 29 kg/m2, an antral follicle count (AFC) > 12, both ovaries present, with regular menstrual cycles and recruited according to the clinical and legal requirements of the Spanish Act for Assisted Human Reproduction: Reproductive Act (RD 9/2014) which includes: a psychological interview, gynecological examination and a rigorous screening for infectious diseases and genetic abnormalities. Donors signed the corresponding informed consent form during enrollment. | |

| | | | |
|--|-----------------|--|--|
| Reporting group values | Tail | | |
| Number of subjects | 149 | | |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |
| Age continuous Units: years arithmetic mean standard deviation | 24.52 ± 5.97 | | |
| Gender categorical Units: Subjects | | | |
| Female | 180 | | |
| Male | 0 | | |

End points

End points reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | control group |
|-----------------------|---------------|

Reporting group description:

The used treatment is identical in both arms. The difference between the groups is the moment of beginning of the stimulation as well as the later administration of more FSH activity:
The control group receives the treatment on the 5th day after the cessation of hormonal contraceptive use and also receives additional FSH.

| | |
|-----------------------|-------------|
| Reporting group title | study group |
|-----------------------|-------------|

Reporting group description:

The used treatment is identical in both arms. The difference between the groups is the moment of beginning of the stimulation as well as the later administration of more FSH activity:
The intervention group receives the treatment on the 7th day after the cessation of hormonal contraceptive use and does not receive additional FSH.

| | |
|----------------------------|------|
| Subject analysis set title | Tail |
|----------------------------|------|

| | |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

Subject analysis set description:

All oocyte donors included in the study were healthy women 18 - 32 years, with body mass index between 18 and 29 kg/m², an antral follicle count (AFC) > 12, both ovaries present, with regular menstrual cycles and recruited according to the clinical and legal requirements of the Spanish Act for Assisted Human Reproduction: Reproductive Act (RD 9/2014) which includes: a psychological interview, gynecological examination and a rigorous screening for infectious diseases and genetic abnormalities. Donors signed the corresponding informed consent form during enrollment.

Primary: number of MII oocytes retrieved

| | |
|-----------------|---------------------------------|
| End point title | number of MII oocytes retrieved |
|-----------------|---------------------------------|

End point description:

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

This variable is assessed at the end of the patients' treatments, on the egg retrieval day.

| End point values | control group | study group | | |
|-----------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 81 | 68 | | |
| Units: oocyte | 13 | 9 | | |

| | |
|----------------------------|-------------------------------|
| Attachments (see zip file) | MII oocyte number/Captura.PNG |
|----------------------------|-------------------------------|

Statistical analyses

| | |
|----------------------------|------------------------|
| Statistical analysis title | Wilcoxon rank sum test |
|----------------------------|------------------------|

Statistical analysis description:

For the univariate statistical analysis of qualitative variables, the Chi - square test or Fisher's exact test will be used. For evaluation of normal distributions, the Shapiro - Wilk's test was performed. Depending on whether the variable has a normal distribution, the comparison between means was carried out using Student's t test or Wilcoxon rank sum test.
Values of $p < 0.05$ will be considered statistically significant.

| | |
|---|--------------------------------|
| Comparison groups | control group v study group |
| Number of subjects included in analysis | 149 |
| Analysis specification | Post-hoc |
| Analysis type | non-inferiority |
| P-value | < 0.05 |
| Method | Wilcoxon (Mann-Whitney) |
| Parameter estimate | Mean difference (final values) |

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

between the start of the trial and the last visit of the last patient.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|----------------------|
| Dictionary name | no specific dictiona |
|-----------------|----------------------|

| | |
|--------------------|---|
| Dictionary version | 1 |
|--------------------|---|

Frequency threshold for reporting non-serious adverse events: 0.05 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Only approved medication was used in the trial. This medication is used frequently in ovarian stimulation protocols and it is well tolerated by the patients.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported